Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
63.84
-0.64 (-0.99%)
At close: Mar 28, 2025, 4:00 PM
63.00
-0.84 (-1.32%)
After-hours: Mar 28, 2025, 6:54 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Halozyme Therapeutics stock have an average target of 61.63, with a low estimate of 49 and a high estimate of 75. The average target predicts a decrease of -3.46% from the current stock price of 63.84.
Analyst Consensus: Buy
* Price targets were last updated on Feb 20, 2025.
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 6, 2025 |
| Benchmark | Benchmark | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +17.48% | Feb 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $70 → $72 | Strong Buy | Maintains | $70 → $72 | +12.78% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +9.65% | Feb 4, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $62 → $57 | Hold | Maintains | $62 → $57 | -10.71% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
1.22B
from 1.02B
Increased by 20.06%
Revenue Next Year
1.51B
from 1.22B
Increased by 23.87%
EPS This Year
5.25
from 3.43
Increased by 53.01%
EPS Next Year
6.75
from 5.25
Increased by 28.59%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.3B | 1.6B | 1.9B | ||
| Avg | 1.2B | 1.5B | 1.7B | ||
| Low | 1.2B | 1.4B | 1.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.4% | 31.7% | 25.5% | ||
| Avg | 20.1% | 23.9% | 15.6% | ||
| Low | 13.5% | 16.9% | 6.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.51 | 7.86 | 9.78 | ||
| Avg | 5.25 | 6.75 | 8.11 | ||
| Low | 4.95 | 5.36 | 6.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 60.6% | 49.9% | 44.9% | ||
| Avg | 53.0% | 28.6% | 20.2% | ||
| Low | 44.3% | 2.1% | -5.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.